相关实验视频

Updated: May 16, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

细菌长CM04-06对DSS诱导的小鼠性结肠炎的治疗效果

Xiaofang Li^1,2, Ningning He³, Haoyu Wang^2,3,4

¹BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450000, China.

Journal of applied microbiology

|May 15, 2025

概括

菌长CM04-06是一种有益的益生菌,通过恢复肠道微生物群平衡来缓解炎症性肠病 (IBD). 这项研究表明,CM04-06可降低小鼠的炎症并改善肠道屏障功能.

科学领域:

微生物学微生物学
免疫学免疫学免疫学
胃肠病学胃肠病学

背景情况:

炎症性肠病 (IBD) 的特点是慢性肠道炎症.
肠道微生物群失生症与IBD病原发生有关.
菌长CM04-06是IBD的潜在治疗候选者.

研究的目的:

在小鼠模型中研究Faecalibacterium longum CM04-06对IBD的治疗作用.
确定CM04-06对肠道微生物群组成和炎症标志物的影响.

主要方法:

患有DSS诱导的大肠炎的小鼠用Faecalibacterium longum CM04-06.6进行治疗.
使用元基因组测序分析了肠道微生物群的组成.
评估了疾病活动指数 (DAI),组织学评分和细胞因子水平.

主要成果:

在DSS诱导的小鼠中,CM04-06治疗显著降低了DAI和组织学评分.
促炎性细胞因子 (IL-1β,IL-6,TNF-α) 在结肠和血清中显著下降.
肠上皮质屏障的完整性得到了增强,紧结蛋白和粘素表达增加.
有益细菌如Faecalibaculum rodentium和Bifidobacterium animalis的丰富性增加了.

结论:

菌长CM04-06证明了对肠道炎症的预防和治疗作用.
CM04-06调节肠道微生物群,促进有益细菌,并抑制促炎性细胞因子.
这种益生菌有望通过恢复肠道平衡来控制IBD.

关键词:

便细菌 1 便细菌 1 群组研究5 群组研究5 我们的肠道微生物群4 大基因组测序2 性结肠炎3 在

更多相关视频

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...